Iotrolan is a non-ionic, dimeric iodinated contrast medium developed for diagnostic imaging. It was introduced to improve the safety and tolerability of contrast agents used in radiographic procedures, particularly by reducing osmotic toxicity compared to earlier ionic contrast media. It has been widely used in procedures such as angiography, urography, and computed tomography (CT).
BRAND NAME
Isovist
MECHANISM OF ACTION
Iotrolan acts as a radiographic contrast agent by containing iodine atoms that absorb X-rays. When administered, it increases the contrast between different tissues or structures in imaging studies, allowing better visualization of blood vessels, organs, and body cavities. It does not exert pharmacological effects but enhances image clarity through its physical properties.
PHARMACOKINETICS
Absorption
Iotrolan is not absorbed in the traditional sense, as it is administered intravascularly or into body cavities. It becomes immediately available in the bloodstream following injection.
Distribution
Iotrolan distributes rapidly within the extracellular fluid compartment. It has minimal plasma protein binding and does not cross the intact blood-brain barrier to a significant extent.
Metabolism
Iotrolan is not metabolized and remains unchanged in the body.
Elimination
It is primarily eliminated unchanged by the kidneys through glomerular filtration. The elimination half-life is typically around 2 hours in individuals with normal renal function.
PHARMACODYNAMICS
Iotrolan is pharmacologically inert and does not interact with receptors or enzymes. Its effect is purely physical, enhancing radiographic contrast by increasing X-ray attenuation in areas where it is distributed.
ADMINISTRATION
Iotrolan is administered by intravascular injection (intravenous or intra-arterial) or into specific body cavities, depending on the imaging procedure. The dose depends on the type of examination, patient condition, and body weight. Adequate hydration before and after administration is recommended to reduce the risk of renal complications.
DOSAGE AND STRENGTH
Dosage varies depending on the imaging technique and patient factors. It is typically measured based on iodine concentration and volume administered. The exact dose is determined by the radiologist.
DRUG INTERACTIONS
Iotrolan may interact with other nephrotoxic drugs, increasing the risk of kidney damage. Caution is advised in patients taking medications that affect renal function.
FOOD INTERACTIONS
There are no significant food interactions. However, patients may be advised to fast before certain imaging procedures.
CONTRAINDICATIONS
Hypersensitivity to iodinated contrast media
Severe renal impairment
Certain thyroid disorders (relative contraindication)
SIDE EFFECTS
Nausea and vomiting
Warm sensation or flushing
Headache
Allergic reactions (rash, itching)
Rare: severe anaphylactoid reactions
OVER DOSAGE
Overdosage of iotrolan is uncommon but can occur during diagnostic imaging procedures if excessive amounts are administered. Because it is an iodinated contrast agent, toxicity primarily affects the kidneys, cardiovascular system, and fluid balance.
TOXICITY
The major risks associated with iotrolan include contrast-induced nephropathy and hypersensitivity reactions. Severe reactions are rare but may include bronchospasm, hypotension, or anaphylaxis. Careful screening and monitoring are essential, especially in high-risk patients.
